About Archon Bio
Archon Bio is a company based in Seattle (United States) founded in 2023 by George Ueda, David Baker, James Lazarovits, and Lance Stewart. Archon Bio has raised $20 million across 1 funding round from investors including ARE, Duke University and Madrona. Archon Bio offers products and services including Antibody Cage (AbC) and Generative AI Platform. Archon Bio operates in a competitive market with competitors including Etcembly, SQALE, Plexymer, Maven Bio and Neuromathix, among others.
- Headquarter Seattle, United States
- Founders George Ueda, David Baker, James Lazarovits, Lance Stewart
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Archon Biosciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20 M (USD)
in 1 rounds
-
Latest Funding Round
$20 M (USD), Seed
Oct 30, 2024
-
Investors
ARE
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Archon Bio
Archon Bio offers a comprehensive portfolio of products and services, including Antibody Cage (AbC) and Generative AI Platform.
Engineered proteins for targeted drug delivery and disease treatment.
AI system for creating tunable biologic structures in drug development.
Funding Insights of Archon Bio
Archon Bio has successfully raised a total of $20M through 1 strategic funding round. The most recent funding activity was a Seed round of $20 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Archon Bio
Archon Bio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Duke University and Madrona.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investing in AI, biotech, and technology sectors, focusing on seed and early stages in Seattle and beyond.
|
Locked | Locked | Locked | |
|
Investments in multiple sectors are made by Sahsen Ventures.
|
Locked | Locked | Locked | |
|
Early-stage venture capital is provided to US companies across sectors.
|
Locked | Locked | Locked |
Investor details for Archon Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Archon Bio
Investment portfolio details for Archon Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Archon Bio
Detailed financials for Archon Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Archon Bio Comparisons
Peer comparison for Archon Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Archon Bio
Archon Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Etcembly, SQALE, Plexymer, Maven Bio and Neuromathix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of AI-based platform to engineer novel T cell receptors for cancer immunotherapy
|
|
| Locked | Locked | Locked |
Provides bioprocess optimization services for microalgae and precision fermentation companies.
|
|
| Locked | Locked | Locked |
Develops custom polymer excipients using AI and robotics for pharmaceutical proteins.
|
|
| Locked | Locked | Locked |
Provides AI tools for BioPharma research, workflows, and strategic insights.
|
|
| Locked | Locked | Locked |
Offers decision support software for personalized healthcare models based on patient data.
|
Detailed competitors of Archon Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Archon Bio
Complete news archive for Archon Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Archon Bio
Archon Bio was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Archon Bio is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
James Lazarovits is the current CEO of Archon Bio. They have also founded this company.
Archon Bio is a funded company, having raised a total of $20M across 1 funding round to date.
Provider of computational platform to develop protein therapeutics. It combines antibodies with AI-generated proteins and Antibody Cage that leverages geometric engineering to control biodistribution and engagement to develop therapeutic targets.
Archon Bio offers Antibody Cage (AbC) and Generative AI Platform.
Archon Bio has 7 investors. Key investors include ARE, Duke University, Madrona, Sahsen Ventures, and Washington Research Foundation.